CMS Provides More Flexibility For Medicare Part D Plans On Prior Authorization And Step Therapy For Certain Drugs

DP
Day Pitney LLP

Contributor

Day Pitney LLP logo
Day Pitney LLP is a full-service law firm with more than 300 attorneys in Boston, Connecticut, Florida, New Jersey, New York and Washington, DC. The firm offers clients strong corporate and litigation practices, with experience on behalf of large national and international corporations as well as emerging and middle-market companies. With one of the largest individual clients practices on the East Coast, the firm also has extensive experience assisting individuals and their families, fiduciaries and tax-exempt entities plan for the future.
The Centers for Medicare & Medicaid Services (CMS) published a final rule on Thursday, May 16, 2019 that provides, among other things
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

The Centers for Medicare & Medicaid Services (CMS) published a final rule on Thursday, May 16, 2019 that provides, among other things, Medicare Part D plan sponsors with more flexibility to require prior authorization and step therapy for drugs in protected classes. The rule's intended purpose is to allow Medicare health and drug plans more flexibility in their negotiations for lower drug price, in addition to reducing out-of-pocket costs for enrollees. However, of note, the rule scraped the idea to pass on price concessions negotiated by pharmacies to patients. CMS wanted to implement this policy in plan year 2020, but held off after receiving more than 4000 comments on the issue. Additionally, the final rule did not include CMS's proposed plan to provide certain exceptions for Part D sponsors to reject a protected class drug because of a manufacturer price spike, or to reject a protected class drug if it embodies only a new formulation of an existing product.


For more articles and regular updates on legislative changes, regulatory developments and other news of interest to businesses, professionals and investors in the healthcare industry, please subscribe to Day Pitney's mailing lists.


Click here for more Healthcare Blogs from Day Pitney

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More